In this article we explore the testing of non-inferiority and equivalence hypotheses arising from multiple centers when the assumption of normality is violated. In a multicenter study, the trials are typically conducted at different centers which vary in terms of location, environment, demographics among others, leading to substantial amount of heterogeneity in the patient population. This unexplained variation in a multi-center clinical study is usually modeled using a random effects model, where the centers are assumed to be a random sample from the population of centers. Most research in this direction uses a parametric normal distribution which can be restrictive and may lead to biased result if the actual distribution is nonnormal. In this article, we overcome this parametric assumption by considering a broader class of random effects distribution for the centers. In particular, we develop a novel nested Dirichlet process (nDP) model to explore the sensitivity of the fixed treatment effects under various hypotheses, in the presence of nonnormality. Additional advantage of our proposed method is that it facilitates a hierarchical clustering structure. At one hand it clusters the centers according to their effects, and hence outlying centers can be identified. Simultaneously, subjects from the clustered centers are again clustered together enabling a borrowing of information across similar centers. Further, we present the methodology to test between the models with nDP versus a normal random center effects models. We discuss the results of our proposed methodology in a real example of a multi-center clinical trial on Scleroderma lung study. The results of the analysis along with the extensive simulation study show the advantage of our method when the center effects distribution is not normal.
Introduction
A common goal in clinical trial is to compare several treatments conducted quite often at different centers. Generally, multi-center trials are designed with the objective of demonstrating an overall treatment effect from the combined contributions of all centers. Multi-center trials are thus very common in the field of drug development. The ICH E9 (1998) guidance outlines two main reason for the popularity of multi-center trials. First, it helps to enroll required number of patients in a time bound fashion. Second, multi-center trials provide a better basis for the generalization of the findings as it represents a broader class of patient populations.
As noted by Freeman (1998) multi-center trials consist of many sources of variability due to various factors, viz, location, environment, demographics, etc. Due to this heterogeneity in multi-center trials there are two major sources of variation in treatment response that can be accounted for (Anello et al., 2005) : the variation within and between centers. To account for these variability several researchers assumed a random center effects model to capture the heterogeneity inherent among different centers. Traditionally, a parametric normal distribution are assumed for these random center effects. Since the particular distributions of these latent effect measures can have an impact on conclusions of the trial, routine use of normal distribution would be rather a strong assumption (Higgins et al., 2009) . In this article, we review and illustrate the danger of using a normal distribution in the absence of proper justification. To protect the model from distributional misspecifications, we develop a broader class of flexible nonparametric distribution using the recently developed nested Dirichlet Process (nDP; Rodríguez et al., 2008) .
There has been a wide amount of literature of the mixed model approach to multi-center clinical trials with fixed treatment effects and random center effects. See Patel (2002) for a review. Some other work in a similar direction are in Khatri and Patel (1992) , Rashid (2003) , Thompson (1994) and Gould (2005) . Most of the existing methods assumes a normal distribution. While this rather strong assumption makes the model easy to apply in widely used softwares such as SAS, the accuracy of this assumptions is difficult to check and the routine use of normality in mixed model is routinely questioned by many authors (Rashid, 2003; Ohlssen et al., 2007; Branscum et al., 2008; Higgins et al., 2009) . Normality assump-tion is too restrictive as it suffers from the lack of robustness particularly when the effects across centers show multi-modality and/or skewness, and thus may not provide an accurate estimation of between-center variation. Furthermore, inference on individual center effects can be misleading when the random center effects distribution deviates from normality. The ICH E9 addresses the issue and possible effects of having outliers in multi-center trials. Thus, it is of practical interest to develop statistical model with considerable flexibility in the distributional assumptions of the random effects as well as measurement error. Rashid (2003) developed a rank-based procedure for testing a non-inferiority and equivalence hypothesis for multi-center trials using mixed model. The R estimates are obtained by minimizing a sum of Jackel (1972) type dispersion functions based on intra-center ranks of residuals. However, this method has too much reliance on the central limit theorem and thus may not be realistic when there are fewer studies. Recently Lee and Thompson (2007) used a skewed distribution to reduce the effects of outlying centers, and a mixture distribution have been advocated to account for studies belonging to unknown groupings (Bohning, 2000) . Although the use of a heavier-tailed distribution such as t-distribution provides some robustness, it may not be sufficient to represent the actual distribution of effects. For example, even a heavy-tailed distribution, such as the t, has a unimodal and a symmetric shape and restrictive in the sense that it fails to allow multi-modality, which may arise due to latent sub-populations.
Bayesian semiparametric approach offers a useful alternative in this direction. There have been few work (Burr et al., 2003; Burr and Doss, 2005; Ohlssen, et al., 2007) on using a Dirichlet process (DP) prior in a multi-center clinical trials. A Dirichlet process consists of a control parameter and a baseline distribution which can be normal. A discrete mass points are drawn from this baseline distribution and how close the discrete distribution is to the baseline depends on the value of the control parameter. Thus the fitted random effects distribution using DP is flexible enough and has the potential to be robust to departures from a normal distribution while having good performance if the actual distribution is normal. Recently, Branscum et al. (2007) developed a Pólya tree method in a meta-analytic framework.
We consider a broader class of random effects distribution for the centers. In particular, we develop a novel nested Dirichlet process (nDP) model to explore the sensitivity of the fixed treatment effects under various hypotheses, in the presence of non-normality. Additional advantage of our proposed method is that it allows a hierarchical clustering structure, whereby the centers clusters according to similarity of their effects, and hence outlying centers can be identified, and at the same time subjects from the clustered centers are also cluster borrowing information from similar centers. Further, we present the methodology to test nDP model versus a normal random center effects model. As mentioned, although semiparametric Bayesian models have been previously used in multi-center clinical trial data, to our knowledge this is the first systematic attempt to use the nDP for this kind of mixed model.
Motivating Data: Scleroderma Lung study
Our method is primarily motivated by the Scleroderma lung study (Tashkin et al., 2006) , which is a double blinded, randomized clinical trial. The aim of the trial was to evaluate effectiveness of oral cyclophosphamide (CYC) versus placebo in the treatment of lung disease due to scleroderma. Scleroderma is an autoimmune connective-tissue disorder that is characterized by microvascular injury, excessive fibrosis of the skin, and distinctive visceral changes that can involve the lungs, heart, kidneys, and gastrointestinal tract. A number of agents have been evaluated as treatments for scleroderma-related interstitial lung disease, but none have been proven effective. Only CYC has shown promise in slowing down the decrease or even improve the forced vital capacity (FVC) over time. In this study our primary outcome is forced vital capacity (FVC), as percentage predicted) determined a 3-month intervals from baseline. At 13 clinical centers throughout the United States, the study enrolled 158 patients with scleroderma, restrictive lung physiology, dyspnea, and evidence of inflammatory interstitial lung disease on examination of bronchoalveolar-lavage fluid, thoracic high resolution computed tomography, or both. Patients received oral CYC (≤ 2 mg per kilogram of body weight per day) or matching placebo for one year and were followed for an additional one year. Pulmonary function was assessed in every three months.
We are interested in evaluating whether oral CYC can either improve %FVC scores.
The study enrolled 158 patients with scleroderma-related interstitial lung disease, who were randomized to receive either CYC (2mg/kg) or identical-appearing placebo for 18 months.
Since the study was conducted across 13 centers, it is important to assess the treatment effect when adjusted for the random center effects. Thus, in this paper we develop a model to test the effectiveness of the treatment CYC over placebo and assume a nDP for the random center effects. One of the scientific interest is to find the centers whose patients populations behave similarly. Out of the 153 patients, 145 completed at least six months of treatment and were included in the analysis.
The rest of the paper is organized as follows. In Section 2, we present the basic model, normal random center effects, the nDP preliminaries and state the hypothesis of interest.
Section 3, gives the nDP model as a generalization of the basic random effects model, and Section 4 gives the posterior distributions of the parameters. Section 4 describes the simulation study and Section 5 described the analysis of the data from Scleroderma Lung Study.
Section 6 have the discussion.
Background

Basic Model
In the following we describe the basic model with the existing normality assumption to put our new model in perspective. Let Y ijt be the response of the i-th subject from j-th center under t-th treatment; i = (1, 2, · · · , n j ), j = (1, 2, · · · , C), t = (1, 2, · · · , T ). Rashid et al. (2003) assume the following normal random center effects model (without covariate) for multi-center clinical trials:
where θ t is the fixed t-th treatment effect, β j is the j-th center effect, γ = (γ 1 , . . . , γ r ) ⊤ is a r × 1 dimensional vector of coefficients associated with r × 1 dimensional vector of covariates w ij = (w ij1 , w ij2 , . . . , w ijr ) ⊤ and e ijt are the random measurement errors. The basic assumptions in (1) is that the random center effects and the errors are independent, and are both normally distributed with zero means.
Although in model (1), the basic assumption of the random center effects is Gaussian, as we discussed this assumption is questionable and inference can be biased under possible misspecification of this normality assumption. Thus, the problem we address in this article is to broaden the class of distribution of the random center effects. In particular, we assume that the center effects come from some unspecified distributions. This allows more flexibility and robustness in the modeling of the observations from different centers when they do not seem to have come from a common distribution, but may have come from a mixture of normal distributions, a distribution with heavier tails, or from some other distributions which cannot be easily specified. Use of nDP is a robust generalization as it has the potential to capture these departures from a normal distribution while having good performance if the actual distribution is normal.
Based on the above model (1) an important question is to assess the efficacy of the treatment effect by pooling the data across the centers. There are some comments in this regard in the ICH E9 guidance (1999) which is described in detail and Annello et al. (2005) .
Based on these documents, there are two main categories of hypotheses in assessing treatment efficacy: one is testing equivalence between treatments, where the null hypothesis is that the difference between the active comparator and new drug is within a pre-specified limit; while the other one is testing for non-inferiority where the aim is to show that the new drug is not less effective than the control by more than a defined margin.
Although not exhaustive, we list the following three potential hypotheses:
This is a general hypothesis in multi-center trials. Accepting H 0 in this hypothesis implies that there is no significant treatment effect in the study and thus treatments are not heterogeneous.
This hypothesis assesses the equivalence of any two treatment (including placebo) within a given range.
Accepting this hypothesis demonstrates a new treatment is not worse than an active control by more than a specified margin.
The nested Dirichlet process
Since Ferguson (1973) described the Dirichlet process (DP) as a random probability measure that can be viewed as a distribution on distributions, use of DP has become popular in the literature of nonparametric Bayes estimation (see, for example, Antoniak 1974; Lo 1978 Lo , 1984 Escobar 1988 Escobar , 1994 West 1995, Ghosh et al., 2009) . Let DP(αH) denote a DP with base measure H and precision α > 0. Replacing H by another DP, Rodríguez (2007) and Rodríguez et al. (2008) 
and
where
with beta(a, b) representing a beta probability distribution with parameters a and b on the (0, 1) interval. The nDP naturally induces clustering in the space of distributions as a consequence of the almost surely discreteness feature of Q, illustrated by (2). Specifically, there is a non-zero probability P(F j = F j ′ |H) = 1/(1 + α) that two distributions F j and F j ′ follow the same random distribution F * k defined by (3). Furthermore, the nDP enables clustering between samples from the distributions in the collection. That is, samples from one single F j , or from F j and F j ′ , j ̸ = j ′ , are correlated, and possibly identical. 
, which is always less than the correlation 1/(1 + ρ) between two samples from the same F j . See more discussion on nDP in Rodríguez (2007) and Rodríguez et al. (2008) .
nDP Model and Methods
Here we generalize the model as described in (1) with covariates and use nDP to better model the heterogeneity among centers. We assume that
where β ij denotes the effect of the i-th subject at the j-th center, thus allowing for a nested subject effect, and e ijt iid ∼ N(0, τ −1 ). Generalizing the normality assumption for the center effects in (1), we assume that
This formulation for the center effects has the following interpretations:
(i) (Heteroscedasticity) Different subjects i in different centers j may be influenced by different center effects.
(ii) (Exchangeability) For different subject i in the same center j, the center effects β ij are independent and identically distributed for all treatments t = 1, . . . , T .
(iii) Centers are clustered according to their effects on the response, and hence, outlying centers can be identified.
(iv) Simultaneously, subjects from similar centers are clustered together according to the effects attributed by centers. That is, being clustered together this allows borrowing information across centers that are similar.
We assumed standard choices for the prior distributions. Hence, given the covariates
are assumed to satisfy the following hierarchical model hereafter referred to as the nDP model.
where As a consequence of the unique characterization of a DP in terms of the Pólya urn distribution of Blackwell and MacQueen (1983) the posterior distribution of the above nDP model can be represented in the form of a hierarchy of two layers, in which there is a Pólya urn distribution in each layer and the Pólya urn distribution at the top layer depends on that at the bottom layer. Though there exist explicit expressions for the two Pólya urns, handling of two such nested Pólya urns turns out to be quite cumbersome due to their complicated dependence structure, resulting in extreme difficulties implementing the Pólya urn Gibbs sampler in Escobar (1988 Escobar ( , 1994 , which is one of the most popular Markov chain Monte Carlo method for sampling from the posteriors in nonparametric models involving DP, for computations of posterior quantities in this model. For the explicit expressions of the Pólya urns for a nDP, one may refer to Rodríguez (2007) .
Posteriors
Following Rodríguez (2007) and Rodríguez et al. (2008) , we replace the stick-breaking representations of the DP priors for both F j and F * k given in (2) and (3) by their almost sure truncation approximations which are finite sums of K and L elements, respectively. That is,
where β * lk
. The finite dimensionalities of (8) and (9) allow us to express the Bayesian semiparametric model (7) entirely in terms of a finite number of random variables. Because of the nature of their prior distributions, these random variables can be drawn from some standard multivariate distributions. We assign them into the following four groups or blocks of parameters, . As shown below, the knowledge of these two vectors of classification variables provide an equivalent expression of the likelihood of the observed data. According to model (7), the likelihood of the observed response Y ijt = y ijt from the i-th subject, receiving t-th treatment in j-th center, which is associated with a covariate vector w ij , is denoted by
It can be equivalently expressed as
Generalizing the idea of the blocked Gibbs algorithm of Ishwaran and James (2001) , based on this equivalence relation of the likelihood, an iterative algorithm (discussed in Appendix)
cycling through four steps, in which each step draws one of the four desirable blocks of parameters conditioning on all the other variables, can be derived for sampling random variates of the four blocks of parameters from their joint posterior distribution for evaluating posterior estimates of any quantity of interest in the problem.
Implementation of the iterative algorithm for M , some large number, cycles results in a
Markov chain of realizations of the four blocks of parameters. Suppose that a Markov se-
T ) is generated for the treatment effects (θ 1 , . . . , θ T ). The posterior probabilities for different hypotheses about any relationship between the treatments, equality, equivalence, or non-inferiority, can be approximated by sample probabilities of the events of interest obtained from the posterior samples. For instance, the probability of equivalence of any two treatment
, and the probability of non-inferiority of the t ′ -th treatment effect θ t ′ to the t-th treatment
For purpose of investigation of accuracy in the estimation or drawing prediction of any new observation, one can make use of density estimates of any observation y associated with t-th treatment in the j-th center and covariate vector w, that are in general computed as
where f
is defined as in (10) according to posterior samples of the unknown parameters in the k-th iteration, denoted by θ and τ (k) , for subjects associated with the t-th treatment from the same center j. In particular, for the nDP model, suppose that in the
denotes the posterior draw of the center effect β ij for the i-th observation in the j-th center according to classification variables ξ (k) ij and ζ
where I {At(i,j)} is an indicator function for the event that the i-th observation in j-th center is associated with t-th treatment, and
is the total number of observations associated with t-th treatment among all n j observations in j-th center. For the normal model, β
, w) as the summand is constant for any i and the total number of summands equals N j (t).
Model Comparison
To our knowledge, the random effects model (7) is the only direct generalization of the normal/Gaussian model considered in the literature, defined as in (1), using nDP. Thus, it is important to formally test the utility of nDP over simple normal model. However, developing a formal Bayes factor for this purpose can be tough as in general, it is difficult to compute a Bayes factor in any Bayesian nonparametric mixture model involving DP since exact evaluation of the marginal likelihood/density of the observations requires performing a multi-fold integration with respect to the Pólya urn distribution or calculation of a finite sum with total number of summands roughly of magnitude of the Bell's number. Basu and Chib (2003) proposed a non-iterative algorithm based on the collapsed sequential importance sampler developed in MacEachern et al. (1999) , which is also discussed in the context of weighted Chinese restaurant processes by Lo et al. (1996) , to approximate the latter sum.
See also Hayakawa et al. (2002) who applied the same algorithm to evaluate a Bayes factor in Bayesian mixture hazard models involving gamma and weighted gamma processes. To the best of our knowledge, no one has proposed any iterative algorithm for these proposes.
Furthermore, since an extension of such an non-iterative algorithm for posterior inference of models involving nDP is not available yet, it is practically impossible to approximate the marginal likelihood of the nDP model (7), and thus, in turn, to evaluate a Bayes factor in the model.
However, the Bayes factor has several other potential problems (Gelfand and Dey, 1994) , the most significant being numerical instability. Therefore we consider an alternative predictive measure of model performance, introduced by Geisser and Eddy (1979) 
with f defined in (10), is the estimate of the CPO for the i-th observation from j-th center.
Specifically, for the nDP model,
For the normal model, it takes the same form as CPO
Simulation Study
In this section, we present numerical examples designed to demonstrate the ability of the nDP model in providing accurate estimates for all of the fixed treatment effects, the random center effects, and the covariate effects. Simulation results based on the nDP model are obtained by implementing the introduced iterative algorithm with truncation levels in (8) and (9) 
implying that E(α) = E(ρ) = 1, which is a common choice in the literature, and P (α > 3) = P (ρ > 3) ≈ 0.006.
Simulated Data
Six different sets of simulated data are generated according to (4) based on the following set-up. There are T = 2 different treatments with known effects θ 1 = −θ 2 , 4 different centers with random effects β ij distributed according to different mixtures of known distributions, and the error term e ijt follows a normal, or a Student's t distribution, or their mixtures.
Except the last dataset, the number of independent observations from each center is given by n j = 50, and hence, the sample sizes of all datasets are 200. For purpose of comparison, these datasets are also analyzed by the normal random center effects model, which differs from (7) with β ij replaced by β j , for i = 1, . . . , n j , and
). This alternative model is referred here as the normal model.
In the first dataset, θ 1 = −θ 2 = 0.5, there are no covariates, and both β ij and e ijt follow mixtures of normals, where 
with all n j = 50, and e ijt ∼ 0.3N(−2, 1) + 0.4N(0, 1) + 0.3N(2, 1).
First, the posterior probability of equivalence of the two treatments, that is, θ 1 = θ 2 , is approximated by the nDP model as Based on the second and the third simulated datasets, we aim at providing an in-depth study of the performance of the nDP model and at demonstrating the superiority of the nDP model over the normal model when dealing with data involving probably some extreme values. In these two datasets, the treatment effect θ 1 remains as 0.5, there are again no covariates, and β ij are distributed as in the first dataset except with zero standard deviations in all the components of the mixture distributions defined in (14) (that is, for instance, β i1 is distributed as a two-point mixture at 0 and 3 with respective weights 0.6 and 0.4). The error distributions in the two datasets from which e ij are generated are chosen to be the Student t distributions with 5 degrees of freedom and 1 degree of freedom, respectively, which possess thicker tails than the mixture of normals in the case of the previous dataset. Estimates of posterior probability of equivalence of the two treatments by both methodologies, not reported here, are all close to zero. Table 1 summarizes the posterior probability estimates of the non-inferiority of θ 1 to θ 2 , for some ∆ > 0, from the two methodologies. The probability estimates, produced by the proposed nDP model for the center effects distributions, roughly equal to 99% in all cases and, are always larger than those produced by the normal model.
Moreover, it seems that the normal model fails to provide as strong evidence as the nDP model in supporting the non-inferiority of θ 1 to θ 2 , as the resulting probability estimates are only ≈ 86% when the error distribution is a thick-tailed Cauchy distribution (i.e., for the third dataset). than all the other cases in the same figure. In summary, the flexible nDP model seems to be more powerful in estimating the treatment effects than the normal model when the data are generated from distributions with thicker tails than normal.
[ Table 1 Next, we look at the performance of the nDP model when the data depend on some covariates. The fourth and fifth datasets differ from the third dataset, which has a Cauchy error distribution, in two aspects. First, there is one covariate from which the observations are generated according to (4) with coefficient γ = −5. The covariates w ij follow a uniform distribution on (−1, 1) and a normal distribution N(0, 1.5 2 ), respectively, in the two datasets.
Second, the center effects β ij follow the distributions in (14). Finally, we scrutinize for how the special clustering features of the nDP model benefit inference in this context of meta-analysis with the aid of the last simulated dataset, which is a variant of the second dataset. This sixth dataset is identical to the second one in terms of involving no covariate, and same distributions of β ij and of the errors e ij , but the treatment effects are chosen to be smaller as θ 1 = 0.05 in a way to illustrate the ability of the methods in estimating treatment effects of negligible magnitudes compared with magnitudes of the center effects and the errors. Furthermore, the sample size n j from each center is increased from 50 to 400. According to the probability estimates of both the equivalence of the two treatments and the non-inferiority of θ 1 to θ 2 defined with ∆ = 0.01, given in Table 2 , it seems that the nDP model outperforms the normal model by a small margin. estimates of the center effects, we selected the "best", or the most representative, iteration that corresponds to the largest value of a proxy of LPML, denoted by LPML (k) , which is defined as in (13) with CPO ij replaced by
From the resulting "best" iteration, the estimate of θ 1 equals 0.032, which is close to either [ Table 2 
Application to Scleroderma Lung Data
We analyze the Scleroderma lung study as described in Section 1.1. Our main goal here is to assess the efficacy of the oral CYC treatment over the placebo while accounting for the center effects. We take the difference of FVC at baseline from FVC values at week 18th as the endpoint here, and fit the following model without any covariate (Inclusion of covariate can be done in a straightforward way), −24.405, −9.298, −1.173, 0.331, 14.922 and 26.505. Center effects from centers 2 and 10 are estimated to be among −22.229, −10.19 and −1.334.
[ Figure 7 about here.]
Conclusion
Multi-center clinical trial has become a popular and useful tool for quantitative synthesizing and summarizing information in the medical literature. Given the availability of reliable data, a multi-center trial should employ robust methods. However, there is empirical evidence to suggest that the use of robust methods is low. The random effects multi-center model is a parsimonious way of accounting for within-center and between-center variation. In this research, we have provided a general modeling framework to analyze the multi-center clinical trial in a mixed model framework. This mixed model framework provides a useful way of describing typical data from multi-center trials. While it is argued that the routine use of normal distribution may bias the inference on treatment effects, it was also of interest to cluster the centers behaving similarly interms of patient population. To achieve this goal, we developed a novel Bayesian semiparametric model where we account for the nested center effects using the nDP.
Using a thorough simulation study, and application to a real dataset, we have demonstrate the ability of the nDP model in providing accurate estimates of the parameters of interest particularly when the random center effects is not coming from normal. Since our model can provide a way to evaluate the treatment effects correctly even under the distributional misspecification, our research can serve as a useful tool for deriving better analysis of multicenter clinical trials. The insensitivity to outliers and the nice clustering behavior of the center effects make our nDP approach an important tool in detecting outlying centers and a robust alternative to the traditional parametric analysis.
Appendix
An iterative algorithm for sampling random variates of (ζ, ξ, π * , ω * , β * , α, ρ), γ, τ , and (θ 1 , . . . , θ T ) from their joint posterior distribution cycles through the following four steps.
1. Sampling of (ζ, ξ, π * , ω * , β * , α, ρ) for the center effects are carried out through the following ste4ps:
(a) Sample the classification variables ζ j for j = 1, . . . , C from a multinomial distribution with probabilities
(b) Sample the classification variables ξ ij for j = 1, . . . , C and i = 1, . . . , n j from a multinomial distribution with probabilities
where m k = ∑ C j=1 I {ζ j =k} is the number of distributions among F 1 , . . . , F C assigned to component k in (8), and constructing π *
∑ n j i=1 I {ζ j =k,ξ ij =l} is the number of center effects assigned to atom l of distribution k in (9), and constructing ω * lk = v * lk
where gamma(a, b) represents a gamma random variable X with density h(x|a, b) ∝
2. Sample γ from its full conditional distribution,
where ϕ r (·|0, Σ γ ) is a r-variate normal density with mean vector 0 and variancecovariance matrix Σ γ . For instance, when γ = γ is univariate and is distributed as
where w ij is the covariate for i-th subject from j-th center.
3. Sample τ from its full conditional distribution,
That is,
4. For identifiability issue, assume that sum of all θ i 's equals zero, that is,
with M being the total number of observations among N = ∑ C j=1 n j satisfying the events {t = s} or {t = T }, and
4 * When there are T = 2 treatments, we assume that θ 1 = −θ 2 ≡ θ for identifiability issue. We sample θ 1 from its full conditional distribution,
, and Frequency histograms of center effects from the "best" iteration based on the sixth simulated dataset. True values of the center effects are 0, 3, 5, and 10 from top row to bottom row. The FVC data (histograms) and density estimates (solid lines) of observations associated with the 2 treatments (left to right) in the 13 centers except center 9 (left to right; top to bottom) based on estimates from the "best" iteration by assuming nDP on center effects distributions. 
